|Newbie Abiomed edges out Netflix as S&P 500’s top YTD gainer|
Jessica Dye in New York
June 29, 2018
Abiomed — which was moved from the S&P MidCap 400 to replace Wyndham Worldwide in the benchmark S&P 500 starting May 31 — has risen 120 per cent in the first six months of the year, according to Thomson Reuters data. Among analysts, Abiomed has five “strong buy” ratings, four “buy”, two “hold” and no sells, with a mean price target of $418.33, according to Thomson Reuters data.
[One has to subscribe to read the rest of the article]